A venture firm founded in 2015 with offices in USA and Israel. The firm invests in multiple sectors, including the life sciences, in pre-seed and seed stage companies; within healthcare, therapeutics, diagnostics and R&D tools companies developing platform technologies. The firm invests early, often acting as the first institutional capital, investing just after the initial stages of product development. The firm generally leads rounds, investing between $.5-5M in rounds no larger than ~$7M. While the firm has to this point invested in US and Israeli companies, it will also consider European and Canadian companies as well.

Within healthcare, the firm is interested in platform technologies in therapeutics and diagnostics/R&D tools. The firm is agnostic to indication and modality, and is looking for companies that have multiple avenues of development to reach the market. Previous investments include companies building CRISPR technologies, post-treatment monitoring, -omics-based drug development, CAR-T and high-throughput screening. The firm does not invest in digital health or medical devices.

The firm acts as a lead investor. Even though they invest early, the firm prefers that the company have at least two full time co-founders before investing. The firm does take a board seat after investing, and is an active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A wholly owned subsidiary of a leading venture capital firm headquartered in Asia was established to focus on US-based biotechnology companies. The firm is interested in opportunities at all stages of development and can allocate between $500 K up to $20 M in equity investments, acting as a lead or follow on.

The firm is currently focusing on the areas of immuno-oncology, gene therapy, ophthalmology, and platform technologies. Previous investments include companies targeting clinical stage small molecule therapeutics for oncology, cyclic peptide drugs for immuno-modulation in chronic inflammatory diseases, and delivery methods and therapeutics for blinding diseases of the eye. The firm invests only in therapeutics, and is very open to investing in early-stage, pre-clinical assets. The firm has been working with a large network of universities and tech transfers to identify promising early-stage opportunities.

The story behind the company and management team is important to the firm. The firm looks for a cohesive business plan and strategy, and are especially interested in opportunities with potential to expand into the Asian market. The firm has a strong network of pharmaceuticals and investors in South Korea that can support market entry. The firm is open to both leading and co-investing, and seeks board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Canada-based venture capital firm is investing out of a fund that invests in both companies and other funds with aligned interests. The firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology (i.e., SAAS, Fintech). The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.

The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.

The firm does not have specific requirements on companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office/venture capital firm based in the USA manages an evergreen fund that operates free from the constraints of traditional venture capital funds. The firm seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2006, a specialized healthcare and life sciences investment firm with over a half-billion dollars in capital under management invests in early-stage companies (Seed/Series A) developing innovative new medical technologies, biotechnologies, and digitally-enabled healthcare services. The firm generally invests $4-8 million of equity capital per round and up to $10-20 million over the investment life. The firm is actively investing and will make 3-5 investments in 2021. The firm nationally and has offices in Austin, TX, and Boston, MA.

The firm is currently looking for companies developing Medical Devices, Therapeutics, Diagnostics, and Healthcare IT products. For medical devices and therapeutics, the firm is open to the full spectrum of subsector and indication and will consider companies developing orphan indications. In HealthTech, the firm is interested in AI-enabled clinical/diagnostic/workflow platforms but will also consider other companies that fall into the broader Healthcare IT space as well, including mobile health companies developing consumer-facing apps. They will consider companies with proprietary platform technologies as well as single/multiple asset companies.

As an early-stage investor, the firm invests almost exclusively in pre-revenue companies, with significant ownership opportunities. They look for experienced management teams, help build the team, and require a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.